Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis.

PubWeight™: 0.87‹?›

🔗 View Article (PMID 10632327)

Published in Clin Cancer Res on December 01, 1999

Authors

M I Koukourakis1, C S Flordellis, A Giatromanolaki, S Koukouraki, A Kapsoritakis, S Potamianos, G Retalis, E Sivridis, B Salsaa, A L Harris, M I Maragoudakis

Author Affiliations

1: Tumour and angiogenesis Research Group, Iraklion, Crete, Greece. targ@her.forthnet.gr

Articles by these authors

Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42

Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38

The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21

Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49

Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28

Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10

Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91

Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res (1997) 3.49

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35

Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33

HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10

Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07

Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76

Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71

Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66

Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64

eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57

Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52

Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47

Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44

Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38

Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35

Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am J Gastroenterol (2000) 2.33

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29

Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26

Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23

Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21

Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20

Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19

Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol (2000) 2.18

Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol (1999) 2.17

Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol (2000) 2.11

Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10

Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem (1998) 2.08

An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature (1988) 2.07

Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07

Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet (1993) 2.03

A common onc gene sequence transduced by avian carcinoma virus MH2 and by murine sarcoma virus 3611. Science (1984) 1.93

Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene (2010) 1.93

Voltage dependence of junctional conductance in early amphibian embryos. Science (1979) 1.90

A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res (1994) 1.89

Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circ Res (1995) 1.84

Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83

Targeting gene expression to hypoxic tumor cells. Nat Med (1997) 1.82

Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81

bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81

Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol (2000) 1.78

The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer (2011) 1.77

Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74

Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74

Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res (1994) 1.72

Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70

Gating of gap junction channels. Biophys J (1984) 1.70

The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (1990) 1.69

Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer (2003) 1.67

Cytokine networks in solid human tumors: regulation of angiogenesis. J Leukoc Biol (1994) 1.66

hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer (2003) 1.65

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer (1992) 1.62

Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res (2000) 1.60

New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene (2010) 1.60

Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int J Cancer (1988) 1.59

Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res (1993) 1.58

The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57

Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene (2000) 1.57

Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer (2000) 1.57

Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res (1995) 1.56

The ubiquitin-proteasome pathway in cancer. Br J Cancer (1998) 1.56

Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A (1995) 1.54

Carboplatin or cisplatin? Lancet (1988) 1.53

First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53

Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J (Clin Res Ed) (1987) 1.52

Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer (1990) 1.52

O6-Methylguanine-DNA methyltransferase of human lymphoid cells: structural and kinetic properties and absence in repair-deficient cells. Cancer Res (1983) 1.52

Avian carcinoma virus MH2 contains a transformation-specific sequence, mht, and shares the myc sequence with MC29, CMII, and OK10 viruses. Proc Natl Acad Sci U S A (1983) 1.51

Pseudomonas aeruginosa urinary tract infection in children: risk factors and outcomes. J Urol (2011) 1.49

Ways of escape: are all tumours angiogenic? Histopathology (2001) 1.48

Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J Clin Pathol (1992) 1.48

Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol (2003) 1.47

Gap junctional conductance: comparison of sensitivities to H and Ca ions. Proc Natl Acad Sci U S A (1982) 1.47

Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol (1997) 1.47

Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res (2001) 1.47

Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer (1998) 1.46

Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res (2001) 1.46